Enteroaggregative E. Coli

You came back from a trip with diarrhea that will not quit. A standard stool culture came back negative, which feels like a dead end but isn't one: routine cultures usually don't test for this E. coli type. Gene-based stool panels can, and in two traveler studies it showed up in about one in seven symptomatic returning travelers.

The hard part comes after the result. A positive is not automatically the cause of your symptoms, because plenty of healthy people carry this bacterium too. What the result gives you is a name for a suspect, and a reason to look at what else showed up alongside it.

What the Test Actually Detects

EAEC (enteroaggregative Escherichia coli) is one of several disease-causing versions of E. coli. It is not a single strain but a category. The old definition came from behavior: the bacteria pile onto gut-lining cells in a stacked-brick pattern and build a sticky film there.

The lab doesn't watch that behavior happen. It looks for genes associated with aggregative strains, most often aggR and aatA on FDA-cleared panels, and sometimes aaiC, aap, or sticky-fiber genes in research assays. When strains carry aggR plus the sticky-fiber genes, nearly all of them show the stacked-brick pattern in lab studies. Single-marker results are less tidy.

That shortcut has a consequence. A sizable share of isolates carrying a classic marker fail to show the clumping behavior when tested on cells. The genes and the behavior are not the same thing.

Traveler's Diarrhea

This is where the test earns its place. Among symptomatic international travelers, EAEC turns up in 13.4% to 14.7% of cases in two Barcelona studies, making it one of the common bacterial findings in traveler's diarrhea. Across studies, detection in symptomatic returnees has ranged from the low teens to far higher in small molecular cohorts, partly because newer gene-based tests find more than older methods.

Recent travel is the single biggest thing that changes how much weight to put on a positive. In a Norwegian study of 9,487 diarrheal episodes and 375 healthy controls, EAEC was common in stool from people with diarrhea and recent international travel, but domestically acquired EAEC showed no independent link to diarrhea overall. Same organism, same test, very different meaning depending on where you picked it up.

A Spanish multicenter study adds a useful caution: non-travel EAEC may still matter in young children. It found EAEC often, especially in children five and under, but its child case-control analysis did not prove the organism was the cause.

So if you got sick after a trip to a high-prevalence region and this is the only thing that turned up, it is a reasonable explanation for your symptoms. If you're an adult with no travel, symptoms already improving, and no inflammation, a lone positive is more likely to be a passenger.

Acute and Persistent Diarrhea

A meta-analysis pooling 41 case-control studies found EAEC can cause acute diarrhea. That evidence is related to this test, but not identical to it: most studies grew bacteria from stool and tested behavior on cells, while modern panels look directly for genes in stool. The strongest signals were in adults living in developing regions and in international travelers to developing regions, where detection was consistently tied to higher odds of diarrhea.

The organism also shows up in some diarrhea that drags on past two weeks. In a 2026 traveler cohort, the ST10 lineage was linked to longer symptoms. In Danish children, certain virulence-gene patterns tracked with whether the illness was brief or persistent.

If your diarrhea has lasted more than a couple of weeks and this comes back positive, that combination is more informative than either fact alone. Persistent illness plus a positive is the pattern where a treatment discussion makes the most sense.

Why a Positive Does Not Mean You Have an Infection

In the VIDA study of children under five across three African countries, EAEC was detected slightly more often in controls without diarrhea (63.9%) than in children with moderate-to-severe diarrhea (58.3%). The study found no significant association between EAEC and severe diarrhea in that population.

The MAL-ED birth cohort, following 2,092 children across eight countries with more than 34,000 stool samples tested, found that 94.8% of infants had at least one EAEC detection by age two. Carrying this organism at some point in early childhood is close to universal in those settings.

In adults in wealthier countries the background rate is much lower. The Norwegian study found EAEC in 2.2% of healthy, asymptomatic people. Still not zero, and still enough to make a lone positive ambiguous.

These two pictures, a real cause of diarrhea in travelers and a harmless resident in healthy children, are not actually in conflict. EAEC is a broad category covering strains with very different gene sets and very different capacity to cause harm. The test tells you EAEC-associated genes are present. It cannot tell you whether the strain is one of the aggressive ones. That is why context does the heavy lifting: travel history, symptom duration, and what else the panel found.

Growth and Gut Inflammation in Young Children

The best-studied long-term signal for this organism has nothing to do with acute illness. In MAL-ED, children with frequent EAEC detections were slightly shorter at age two on the length-for-age scale. That association held after accounting for study site, age, and recent antibiotic use.

Carriage without symptoms also tracked with raised markers of gut inflammation and intestinal damage. These markers are signs of irritation and leakiness in the gut lining, not proof that one positive result is causing harm.

This matters for how you read a positive in a child. The absence of diarrhea does not prove the organism is doing nothing. It also does not make the result an emergency: this signal comes from cohorts in low-resource settings with repeated, heavy exposure, not from a single detection in a well-nourished child.

What Else Is in the Sample

Recent studies show why the rest of the panel matters. In Norway, 64.3% of EAEC-positive diarrheal episodes had another pathogen. In a pediatric hospital study, 68% of EAEC detections had another microbe detected too. Co-detection is the norm, not the exception.

Those co-pathogens are often the cleaner explanation. Norovirus, Campylobacter, Giardia, and Salmonella can each cause more decisive illness than EAEC usually does. In young children, EAEC combined with rotavirus was associated with about seven times the odds of severe disease compared with neither, which tells you the pairing matters more than the EAEC alone.

Read the panel as a whole. If something more clearly pathogenic is sitting next to your EAEC result, that is where attention should go first.

Why a Single Reading Can Fool You

Timing is the biggest problem. PCR positivity for other bacterial gut infections can persist for weeks after symptoms resolve. In one adult longitudinal study, median molecular detection lasted about three to six weeks for Campylobacter, Salmonella, and Shiga toxin-producing E. coli. EAEC may not behave exactly the same, but the caution carries over: a positive test three weeks after an illness may be the tail end of something already over.

• Bacterial load doesn't settle it: labs can report how much DNA was present, but healthy carriers and sick people can show overlapping amounts. A faint signal cannot be dismissed as noise, and a strong one cannot be taken as proof of disease.
• Assays disagree with each other: sensitivity for EAEC runs from 54% to 69% across some platforms, so a negative on one test does not fully rule it out. Specificity is much better, typically 94% to 100%, meaning a positive is usually a real detection of the target genes.
• Genes move between bacteria: some markers sit on mobile DNA packets that bacteria can swap. The gene can be present without a clearly disease-causing strain being present.

What to Do With an Unexpected Result

Start by asking whether the result matches the story. Recent travel, ongoing symptoms, and no competing explanation on the panel is the combination that points toward EAEC as the culprit. No travel, symptoms already resolved, and another pathogen in the same sample points the other way.

Check the rest of the panel before anything else. A Shiga toxin result (stx1 or stx2) changes everything: that is a different pathotype entirely, it can lead to serious kidney complications, and antibiotics are avoided in that situation. Invasive bacteria like Salmonella, Shigella, and Campylobacter each have their own management path. Parasites like Giardia and Cryptosporidium are a common reason travel-related diarrhea persists and need a different drug altogether.

If symptoms are persistent, severe, bloody, or you have a weakened immune system, take this to an infectious disease physician or gastroenterologist rather than treating from the panel alone. The reason is not caution for its own sake: in one pediatric hospital study, 45% of antibiotic courses started after an E. coli detection were judged clinically inappropriate. A positive is an invitation to think, not a prescription.

A culture alongside the panel is worth adding if treatment is on the table. Multi-drug resistance is common in some EAEC cohorts, with resistance to ampicillin and trimethoprim-sulfamethoxazole reported often, and cephalosporin resistance also reported. Only a cultured isolate can be tested for what it actually responds to.

When Repeat Testing Helps

This is not a number you track over time. There is no baseline to establish and no trend to watch, because it's a yes-or-no detection of an organism you either carry right now or don't.

Retesting is worth it in two situations. If symptoms persist after treatment, a repeat panel can tell you whether something else has taken over or was missed the first time. If you tested during or soon after an illness and are now well, a repeat weeks later can confirm the organism has cleared, though prolonged shedding means a lingering positive in a person who feels fine is not itself a reason to treat.

What deserves tracking is the symptom picture: how long, how severe, whether it responds to anything. That history is what turns an ambiguous lab result into a usable answer.